ArticleVaccines2022
Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Emerging and Underdetected Colonization Factors in EnterotoxigenicMicroorganisms · 2026Review
- Review
- A 25-year landscape of Escherichia coli vaccine development: systematic review of human clinical studies.NPJ vaccines · 2026Article
- Recent progress in enterotoxigenicInfection and immunity · 2025Review
- Shigellosis.Lancet (London, England) · 2025Review
- Characterization ofApplied and environmental microbiology · 2025Article
- Conserved antigens for enteric vaccines.Vaccine · 2025Review
- Review
- Determining glycosyltransferase functional order via lethality due to accumulated O-antigen intermediates, exemplified withApplied and environmental microbiology · 2024Article
- Review
- Optimizing Vaccine Trials for Enteric Diseases: The Enterics for Global Health (EFGH)Open forum infectious diseases · 2024Article
- Molecular Signature of Monocytes Shaped by theInternational journal of molecular sciences · 2024Article
- Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate.NPJ vaccines · 2024Article
- A rhesus macaque intragastric challenge model for evaluating the safety, immunogenicity, and efficacy of live-attenuatedFrontiers in microbiology · 2024Article
- Protein-based vaccine candidate MecVax broadly protects against enterotoxigenicInfection and immunity · 2023Article
- Anti-Toxin Responses to Natural EnterotoxigenicMicroorganisms · 2023Article
- The Diversity ofMicroorganisms · 2023Review
- Malnutrition vaccines for an imminent global food catastrophe.Trends in pharmacological sciences · 2022Article
- Frontiers inVaccines · 2022Article
- TheVaccines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
Abstract
background
methodsShigETEC was evaluated in a two-staged, randomized, double-blind and placebo-controlled Phase I clinical trial. A single dose of increasing amounts of the vaccine was given to determine the maximum tolerated dose and increasing number of immunizations were administered with an interval based on the duration of shedding observed.
resultsOral immunization with ShigETEC was well tolerated and safe up to 4-time dosing with 5 × 10
conclusionShigETEC is a promising vaccine candidate that is scheduled for further testing in controlled human challenge studies for efficacy as well as in children in endemic setting for safety and immunogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.